T

he latest flare-up over prescription drug pricing is taking place in Ireland, where two drug makers are at war with the government for refusing to provide coverage for a pair of medicines.

In one instance, CSL Behring (CSL) announced plans to end a compassionate use program later this month for its Respeeza treatment for people with an inherited form of emphysema. The move had previously been signaled if government coverage was not provided, but was formalized after Ireland’s Health Service Executive last month decided the drug is not cost effective.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy